Abstract Details

Title Creatinine and C-Reactive Protein in Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson’s Disease

Topic General Neurology

Presentation(s) Neuroepidemiology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 015

Background Serum creatinine and C-reactive protein have been proposed as potential biomarkers for neurodegenerative diseases. However, longitudinal studies investigating temporal patterns of these biomarkers, including the phase before diagnosis, are rare.

Objective To determine the temporal patterns of creatinine and C-reactive protein before and after the diagnosis of amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.

Design/Methods We performed a case-control study including all newly diagnosed patients with amyotrophic lateral sclerosis (N=525), multiple sclerosis (N=1,815), or Parkinson’s disease (N=3,797) during 2006-2013 in Stockholm, Sweden, who participated in the Stockholm CREAtinine Measurements project. For each case, up to five controls were randomly selected and individually matched by age, sex, and county of residence (N=2625 for amyotrophic lateral sclerosis, N=9,063 for multiple sclerosis, and 18,960 for Parkinson’s disease). We collected testing results of serum creatinine and C-reactive protein for all the individuals and visualized median levels of creatinine and C-reactive protein using locally weighted smoothing curves among cases and controls. A linear mixed model was also applied to explore temporal changes within an individual.

Results

Compared to controls, patients with amyotrophic lateral sclerosis had lower levels of creatinine from two years before diagnosis onward. In contrast, patients with amyotrophic lateral sclerosis had lower levels of C-reactive protein before diagnosis but higher levels after diagnosis, compared to controls. Patients with amyotrophic lateral sclerosis displayed statistically significantly decreasing level of creatinine from one year before diagnosis until two years after diagnosis, whereas increasing level of C-reactive protein from diagnosis until two years after diagnosis. There were no similar patterns noted among patients with multiple sclerosis or Parkinson’s disease, or the controls of the three patient groups.

Conclusions

Patients with amyotrophic lateral sclerosis display distinct temporal patterns of creatinine and C-reactive protein before and after diagnosis, compared to amyotrophic lateral sclerosis-free controls or patients with multiple sclerosis and Parkinson’s disease.

Authors/Disclosures
Can Cui PRESENTER	Miss Cui has nothing to disclose.
Jiangwei Sun	Mr. Sun has nothing to disclose.
	No disclosure on file
Fredrik L. Piehl, MD, PhD (Neuroimmunology Unit, Dept Clinical Neuroscience, Karolinska Institutet)	Dr. Piehl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parexel/Chugai. The institution of Dr. Piehl has received research support from UCB. The institution of Dr. Piehl has received research support from Merck KGaA. Dr. Piehl has received personal compensation in the range of $10,000-$49,999 for serving as a member scientific advisory board with Swedish Medical products Agency.
Honglei Chen, MD, PhD, FAAN (Michigan State University)	The institution of Dr. Chen has received research support from NIH, . The institution of Dr. Chen has received research support from DoD. The institution of Dr. Chen has received research support from Parkinson's Foundation. The institution of Dr. Chen has received research support from MSU GE and Gibby vs. Parky project.
	No disclosure on file
Karin Wirdefeldt, MD (Karolinska University Hospital)	The institution of Dr. Wirdefeldt has received research support from The Parkinson Foundation in Sweden. The institution of Dr. Wirdefeldt has received research support from Swedish Research Council.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file